In follow up to the previous post, the Pharmalot blog published an interview with Brook Baker, a professor in the Program on Human Rights and the Global Economy at Northwestern University School of Law, and a member of Health Gap, Global Access Project. Dr. Baker explains sequence of events in the case and why advocates on both sides have latched onto it.
The Indian Supreme Court postponed its hearing this week. The case will establish patentability for changes to existing drugs, define "enhanced efficacy", set rules for evergreening and will likely have important implications to generic manufacturers and drug availability and pricing in India.
Posted by Bruce Lehr Sep 7th 2011.